- Home
- SPRO vs MNDO Comparison
SPRO vs MNDO Comparison
Compare SPRO & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- MNDO
- Stock Information
- Founded
- SPRO 2013
- MNDO 1995
- Country
- SPRO United States
- MNDO Israel
- Employees
- SPRO N/A
- MNDO N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- SPRO Health Care
- MNDO Technology
- Exchange
- SPRO Nasdaq
- MNDO Nasdaq
- Market Cap
- SPRO 45.7M
- MNDO 39.9M
- IPO Year
- SPRO 2017
- MNDO 2000
- Fundamental
- Price
- SPRO $0.83
- MNDO $2.10
- Analyst Decision
- SPRO Buy
- MNDO
- Analyst Count
- SPRO 4
- MNDO 0
- Target Price
- SPRO $5.00
- MNDO N/A
- AVG Volume (30 Days)
- SPRO 217.5K
- MNDO 46.2K
- Earning Date
- SPRO 03-12-2025
- MNDO 03-05-2025
- Dividend Yield
- SPRO N/A
- MNDO 11.37%
- EPS Growth
- SPRO N/A
- MNDO N/A
- EPS
- SPRO 0.06
- MNDO 0.23
- Revenue
- SPRO $106,455,000.00
- MNDO $21,856,000.00
- Revenue This Year
- SPRO N/A
- MNDO N/A
- Revenue Next Year
- SPRO N/A
- MNDO N/A
- P/E Ratio
- SPRO $12.71
- MNDO $9.05
- Revenue Growth
- SPRO 37.01
- MNDO 2.27
- 52 Week Low
- SPRO $0.74
- MNDO $1.70
- 52 Week High
- SPRO $1.89
- MNDO $2.28
- Technical
- Relative Strength Index (RSI)
- SPRO 44.07
- MNDO 56.56
- Support Level
- SPRO $0.82
- MNDO $2.07
- Resistance Level
- SPRO $0.85
- MNDO $2.13
- Average True Range (ATR)
- SPRO 0.05
- MNDO 0.05
- MACD
- SPRO 0.01
- MNDO 0.00
- Stochastic Oscillator
- SPRO 43.33
- MNDO 78.57
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.